TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04650204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticonvulsant Agent
Description: Given ASD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01851083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow mononuclear cells
Description: BMMNC infusion of either 6x10\^6 cells/kg or 10x10\^6 cells/kg weight.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: Placebo infusion of 0.9% Sodium Chloride
Study: NCT03017768

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acute tryptophan depletion
Description: an amino-acid mixture will be administered without tryptophan (active comparator). After an incubation period of 5 hours esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of depleted tryptophan levels on esophageal sensitivity

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an amino-acid mixture with tryptophan (placebo mixture) will be administered. After an incubation period of 5 hours esophageal sensitivity will be assessed by multimodal stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal stimulation probe
Description: The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
Study: NCT05017467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: undefinedCentella Asiatica Extract
Description: All patients were asked about scar hypertrophy, scar tenderness, and pillar pain.~The scar assessment was performed using the Vancouver Scar Scale (VSS) at the one, three and 6 months after surgery.~Patients were asked to complete pre- and postoperative functional evaluations. The VAS score and QuickDASH test was used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: undefinedCentella Asiatica Extract
Description: All patients were asked about scar hypertrophy, scar tenderness, and pillar pain.~The scar assessment was performed using the Vancouver Scar Scale (VSS) at the one, three and 6 months after surgery.~Patients were asked to complete pre- and postoperative functional evaluations. The VAS score and QuickDASH test was used
Study: NCT00748371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: 40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: 1300mg aspirin: one 650-mg capsule by mouth twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo: one Avicel (cellulose) capsule by mouth twice daily
Study: NCT04332718

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone ECG
Description: Patients who are randomised to the 30-day smartphone ECG monitoring will be contacted within one month from randomisation. Patients will be taught on how to use the smartphone ECG monitoring. Patients are required to monitor their ECG 3 times a day for 30 days. Patients will be contacted during the monitoring period to assess for compliance and to ensure that the recording is done correctly.
Study: NCT03940300

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fresh organic vegetables
Description: Individual participation in this program will take 12 weeks, from screening and enrollment through evaluation. Once enrolled, visits will occur on a weekly basis to ensure that participants receive each week's dose of fresh organic vegetables. At an optional Visit 13, offered 6 months after Visit 1, an additional health screening will be conducted.
Study: NCT01022138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2Bi-armed activated T cells
Description: Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: The association between the \[18F\]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored.
Study: NCT04117529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Collection of 2 blood sample : The first one at the inclusion in the study, the second one between 6 months and 9 months after the inclusion. The sample consists of 2 tubes of EthyleneDiamineTetraAcetic (EDTA) of 7 mL.
Study: NCT00203424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib + Bevacizumab
Description: Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
Study: NCT04182243

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of job satisfaction in emergency health care providers by questionnaire
Study: NCT01010971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide HFA 160 μg
Description: Ciclesonide HFA Nasal Aerosol 160 μg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide HFA 80 μg
Description: Ciclesonide HFA Nasal Aerosol 80 μg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo HFA Nasal Aerosol once daily
Study: NCT01011543

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic techniques in pulmonary tuberculosis
Description: Two different methods to obtain a diagnosis of pulmonary tuberculosis in patients with negative classic sputum samples are compared.
Study: NCT03017768

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Multimodal stimulation probe
Description: The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
Study: NCT03937505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IS-001
Description: intravenous injection of IS-001 investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IS-001
Description: intravenous injection of IS-001 investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No treatment
Description: no drug injection
Study: NCT02721381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImPACT Online
Description: ImPACT Online is an interactive, web-based telehealth intervention that teaches parents to promote their child's social-communication skills during play and daily routines. The intervention content was adapted from Project ImPACT, a manualized parent training curriculum that uses a blend of developmental and naturalistic behavioral intervention techniques, including following the child's lead, imitating the child, using heightened animation, using simplified language around the child's focus of attention, environmental arrangement strategies, prompting, and natural reinforcement during child-directed activities. There is strong empirical support for the intervention techniques for increasing social communication in children, increasing parent fidelity, and child language skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImPACT Online
Description: ImPACT Online is an interactive, web-based telehealth intervention that teaches parents to promote their child's social-communication skills during play and daily routines. The intervention content was adapted from Project ImPACT, a manualized parent training curriculum that uses a blend of developmental and naturalistic behavioral intervention techniques, including following the child's lead, imitating the child, using heightened animation, using simplified language around the child's focus of attention, environmental arrangement strategies, prompting, and natural reinforcement during child-directed activities. There is strong empirical support for the intervention techniques for increasing social communication in children, increasing parent fidelity, and child language skills.
Study: NCT04727385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double Crosslink Microgel
Description: DXM hydrogel is a pH responsive Double Cross-Linked microgel based on single internally cross-linked microspheres (comprising a methacrylic acid-methyl methacrylate-ethylene glycol dimethacrylate copolymer)~The DXM gel is injected into the intervertebral disc (IVD) space via a standardised procedure similar to the routinely-performed Discography procedure. The disc approach described in the discography procedure has been reported to allow the injection of a solution in the centre of the disc. The injection of the gel takes about 2 min.
Study: NCT01809444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone+placebo of Doxycycline
Description: Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks
Study: NCT03625102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol
Description: Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol
Description: Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
Study: NCT03272451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: culprit vessel intervention
Description: ECG guided immediate culprit vessel intervention using a single transradial guiding catheter such as MAC or JL 3.5
Study: NCT03625102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
Study: NCT01789307

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: corn syrup solids
Description: oral ingestion 50 grams, 2 doses

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrose
Description: oral ingestion 50 grams, 2 doses
Study: NCT01432743

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NavX Fusion
Description: Using NavX Fusion to guide catheter ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cartomerge
Description: Guidance of catheter ablation using Cartomerge guidance
Study: NCT06283654

Intervention type: DEVICE
Intervention: 1-lead ECG
Description: patient were handed out a 1 lead ECG device, they were free to use it anyway they wanted, even not at all
Study: NCT02078141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-deoxyglucose (FDG)
Description: 18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq
Study: NCT03131375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group A receives a 50 ml NS infusion containing 1 mcg kg-1 Dexmedetomidine drug Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B, and 0.16 mg kg-1 in Group A. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index , Train of four ratio.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index
Description: Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bispectral index
Description: Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60
Study: NCT02329509

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two stage palate surgical repair
Description: two stage palate surgical repair with a hard palate closure at 3 to 4 years old
Study: NCT03131375

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Train of four ratio
Description: Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure
Study: NCT03272451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional approach
Description: single diagnostic catheter for complete coronary angiography and guiding catheter selection for PCI
Study: NCT01020058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh repair for primary inguinal hernia
Description: Open Lichtenstein repair in local anesthesia using a polypropylene mesh compared to totally extra-peritoneal laparoscopic repair using a polypropylene mesh

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh repair for primary inguinal hernia
Description: Open Lichtenstein repair in local anesthesia using a polypropylene mesh compared to totally extra-peritoneal laparoscopic repair using a polypropylene mesh
Study: NCT02825836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
Study: NCT01809444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline+placebo of Prednisone
Description: Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
Study: NCT02825836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
Study: NCT02077114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine consisting of a peptide derived from the protein IDO
Description: All patients will receive seven vaccines containing IDOlong
Study: NCT03131375

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Train of four ratio
Description: Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure
Study: NCT04408326

Intervention type: DRUG
Intervention: Angiotensin II
Description: Exogenous angiotensin II acts on angiotensin II type 1 receptor and raise blood pressure by vasoconstriction, salt and water retention, and stimulation of aldosterone hormone

Intervention type: DRUG
Intervention: Interleukin-1 receptor antagonist
Description: Interleukin-1 receptor antagonist is an immunomodulating drug aiming to mitigate cytokine storm in COVID-19 patients
Study: NCT01224600

Intervention type: OTHER
Intervention: patients with newly diagnosed PAD (<1year)
Description: patients with newly diagnosed PAD (\<1year) symptomatic or asymptomatic, without any history of previous coronary nor cerebrovascular event, and with no previous investigation of the aorta and cervical arteries were eligible
Study: NCT02329509

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One stage Palate Surgical repair
Description: One stage palate repair at the age of 9 to 24 months old
Study: NCT04571853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PNE-explained group
Description: There are 9 fact sheets overall. And each fact sheet incorporates two pages relating to one main concept. The first of two pages introduces the concept, and the second one quotes important ideas that emerge from the main concept. The 9 main concepts and consequent ideas presented in the fact sheets are based on current scientific research in pain science and have been selected and structured specifically for PNE education for chronic pain patients. The fact sheets have been fully developed and designed by Pain Revolution, a pain educator network founded by Professor Lorimer Moseley, group leader in Body in Mind Research Group from University of South Australia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PNE-read group
Description: The PNE-read group will receive the fact sheets via email along with instructions regarding the content and the procedure to read the content. Instructions will suggest to read only two fact sheets per day during 4,5 days. It will be suggested to take 30 minutes at least for each fact sheet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU group
Description: Participants allocated to this group will maintain treatment as usual (TAU) and will follow the recommendations by their usual health professiona
Study: NCT03493477

Intervention type: OTHER
Intervention: exposure will be abnormal skeletal jaw relations
Description: Class II skeletal jaw relation or class III skeletal jaw relation based on lateral cephalometric radiograph
Study: NCT02640482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABT-493/ABT-530
Description: tablet
Study: NCT01428388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of bevacizumab
Description: 1.25 mg per dose, delivered monthly by intravitreal injection for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of ranibizumab (0.5 mg per dose)
Description: 0.5 mg per dose, delivered monthly by intravitreal injection for six months
Study: NCT00777790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study: NCT00752063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib with Capecitabine and Oxaliplatin
Description: Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
Study: NCT03975465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training
Description: 8 weeks of EMST at 75% maximum expiratory pressure (MEP)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharyngeal Muscle Strengthening Exercises
Description: 8 weeks of exercises designed to increase pharyngeal muscle strength for swallowing
Study: NCT04064190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib(TEW-7197)/ Durvalumab
Description: Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks